Adagio Therapeutics, Inc. ADGI
We take great care to ensure that the data presented and summarized in this overview for Adagio Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADGI
View all-
Mithril Ii Gp LP Austin, TX11.2MShares$37.2 Million27.49% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx10.2MShares$33.9 Million0.58% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million39.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT8.59MShares$28.4 Million1.01% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.93MShares$13 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY3.07MShares$10.2 Million0.8% of portfolio
-
Redmile Group, LLC San Francisco, CA2.29MShares$7.56 Million0.92% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA1.8MShares$5.96 Million1.79% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.25MShares$4.13 Million0.0% of portfolio
Latest Institutional Activity in ADGI
Top Purchases
Top Sells
About ADGI
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Insider Transactions at ADGI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 19
2025
|
William E. Duke Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
29,643
-37.53%
|
$0
$0.57 P/Share
|
|
Aug 19
2025
|
Timothy Edward Lee Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
29,643
-33.31%
|
$0
$0.57 P/Share
|
|
Aug 19
2025
|
Robert D. Allen Iii Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
27,420
-34.07%
|
$0
$0.57 P/Share
|
|
Aug 19
2025
|
Jill Andersen Chief Legal Officer, Secretary |
SELL
Open market or private sale
|
Direct |
49,402
-36.91%
|
$0
$0.57 P/Share
|
|
Aug 19
2025
|
Julie Green Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
29,643
-37.53%
|
$0
$0.57 P/Share
|
|
Aug 18
2025
|
William E. Duke Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
20,013
-20.22%
|
$0
$0.65 P/Share
|
|
Aug 18
2025
|
Timothy Edward Lee Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
20,013
-18.36%
|
$0
$0.65 P/Share
|
|
Aug 18
2025
|
Robert D. Allen Iii Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
18,512
-18.7%
|
$0
$0.65 P/Share
|
|
Aug 18
2025
|
Jill Andersen Chief Legal Officer, Secretary |
SELL
Open market or private sale
|
Direct |
33,352
-19.95%
|
$0
$0.65 P/Share
|
|
Aug 18
2025
|
Julie Green Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
20,013
-20.22%
|
$0
$0.65 P/Share
|
|
Aug 15
2025
|
William E. Duke Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
99,000
+50.0%
|
-
|
|
Aug 15
2025
|
Timothy Edward Lee Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
99,000
+47.6%
|
-
|
|
Aug 15
2025
|
Robert D. Allen Iii Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
99,000
+50.0%
|
-
|
|
Aug 15
2025
|
Jill Andersen Chief Legal Officer, Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
165,000
+49.67%
|
-
|
|
Aug 15
2025
|
Julie Green Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
99,000
+50.0%
|
-
|
|
Dec 31
2024
|
Terrance Mcguire |
SELL
Open market or private sale
|
Indirect |
103,474
-3.26%
|
$0
$0.45 P/Share
|
|
Dec 30
2024
|
Terrance Mcguire |
SELL
Open market or private sale
|
Indirect |
86,545
-2.66%
|
$0
$0.48 P/Share
|
|
Dec 27
2024
|
Terrance Mcguire |
SELL
Open market or private sale
|
Indirect |
83,744
-2.51%
|
$0
$0.52 P/Share
|
|
Dec 26
2024
|
Terrance Mcguire |
SELL
Open market or private sale
|
Indirect |
83,817
-2.45%
|
$0
$0.54 P/Share
|
|
Dec 24
2024
|
Terrance Mcguire |
SELL
Open market or private sale
|
Indirect |
68,161
-1.95%
|
$0
$0.51 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 561K shares |
|---|
| Open market or private sale | 1.9M shares |
|---|